The Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist.

Trial Profile

The Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Betrixaban (Primary)
  • Indications Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2018 Status changed from recruiting to completed.
    • 16 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top